Akebia Therapeutics, Inc. Sustainability Profile
Akebia Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with kidney disease. Founded in 2007, Akebia has made significant strides in the industry, particularly in the area of hypoxia-inducible factor (HIF) stabilisation, which plays a crucial role in managing anaemia associated with chronic kidney disease. The company’s flagship product, vadadustat, is designed to treat anaemia by stimulating erythropoiesis, offering a unique oral alternative to traditional injectable therapies. Akebia's commitment to advancing renal care has positioned it as a notable player in the biopharmaceutical landscape, with a strong emphasis on research and development. With a focus on improving patient outcomes, Akebia continues to explore new avenues in the treatment of kidney-related conditions, solidifying its reputation as an innovator in the field.
DitchCarbon Score
How does Akebia Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akebia Therapeutics, Inc.'s score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Akebia Therapeutics, Inc.'s reported carbon emissions
Akebia Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Akebia may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As a result, Akebia's climate commitments and emissions performance remain unclear, placing them in a context where many industry peers are increasingly adopting transparent sustainability practices and setting ambitious targets. Without specific emissions data or reduction initiatives, Akebia Therapeutics, Inc. may face challenges in aligning with the growing expectations for corporate responsibility regarding climate change.
How Carbon Intensive is Akebia Therapeutics, Inc.'s Industry?
How Carbon Intensive is Akebia Therapeutics, Inc.'s Location?
Akebia Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Akebia Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
